DCTH
Delcath Systems, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
123.93
PEG
1.12
P/B
3.18
P/S
3.95
EV/EBITDA
114.69
DCF Value
$-159.22
FCF Yield
6.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.2%
Operating Margin
0.8%
Net Margin
3.2%
ROE
2.6%
ROA
2.2%
ROIC
0.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $20.7M | $-1.9M | $-0.05 |
| FY 2025 | $85.2M | $2.7M | $0.07 |
| Q3 2025 | $20.6M | $830.0K | $0.02 |
| Q2 2025 | $24.2M | $2.7M | $0.07 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.43
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.